Hi all,I noted in the annual report we were doing a combination...

Hi all,

I noted in the annual report we were doing a combination therapy trial with SNT-5505 and 5-AXA.

Myelodysplastic neoplasms, also known as myelodysplastic syndromes (MDS), are a group of hematologic cancers characterized by ineffective production of blood cells in the bone marrow due to clonal mutations in hematopoietic stem cells.

These mutations lead to the abnormal growth of blood stem cells, resulting in immature blood cells that do not mature properly and often die prematurely.MDS is more common in older adults, typically diagnosed around the age of 70, and can result from previous chemotherapy, radiation therapy, or exposure to certain chemicals.

Symptoms may include fatigue, shortness of breath, frequent infections, and bleeding tendencies due to low counts of red blood cells, white blood cells, and platelets.The condition can progress to acute myeloid leukemia (AML) in some cases.

Treatment options vary based on the severity and include supportive care, medications like lenalidomide and azacitidine, and potentially hematopoietic stem cell transplantation. The prognosis depends on various factors, including the type of cells affected and the presence of chromosomal abnormalities, with an average survival time of 2.5 years after diagnosis.

Reference: Perplexity Ai

The below study is quite full on for most, even I have trouble.

These diseases are niche medicine. Takes years to understand the underlying pathologies and then a chemical combination to possibly alleviate it. I know some drugs inside out yet others I can only start to absorb. Anyway if in a time constraint just look at the liver photos to get an idea of the interaction of SNT-5505 and 5-AXA.

The prevalence of myelodysplastic syndromes (MDS) in the United States is estimated to be between 60,000 and 175,000 cases.

So assume 100 K double that for a world population.Assume $100 K per year per treatment ( seems to be the going rate ).

Market of 10 billion less a 65% discount.So 3.5 Billion sales per year.

PXS-5505 is covered under the patent family WO2020024017, which has its earliest expiry in 2038

Do the maths X by years.




https://www.nature.com/articles/s41467-023-37175-8


Kpax